These data confirmed that the described genetic and other substantial factors affecting TUBB3 transcription directly affect metastatic tumor progression of drug-resistant cancer cells, specifically PTX-resistant tumors with acquired cross-resistance to unrelated drugs (at least to 5-FU and CIS). The gene discussed is TUBB3; the disease is in situ carcinoma.